Cytograft's vision is to revolutionize regenerative medicine by developing a new paradigm in cardiovascular repair that uses cell-based therapies to minimize the role of synthetic biomaterials in the treatment of cardiovascular disease.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player
Cytograft's CSO and inventor of Tissue Engineering by Self-Assembly, Dr. Nicolas L'Heureux, explains the Lifeline™ Technology
link to full size video link to animation